Top Page
Tristel
(LSE:TSTL)
Tristel (TSTL) vs. iShares MSCI United Kingdom ETF (EWC)
Tristel Business Overview & Revenue Model
Tristel Earnings Call Summary
Tristel Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 46.46M | 46.46M | 41.93M | 36.01M | 31.12M | 31.00M |
| Gross Profit | 37.94M | 37.94M | 33.58M | 29.18M | 24.66M | 24.74M |
| EBITDA | 11.47M | 11.47M | 10.01M | 7.90M | 4.46M | 6.70M |
| Net Income | 6.64M | 6.64M | 6.49M | 4.46M | 987.00K | 3.66M |
Balance Sheet | ||||||
| Total Assets | 45.33M | 45.33M | 44.11M | 41.37M | 38.74M | 39.93M |
| Cash, Cash Equivalents and Short-Term Investments | 12.84M | 12.84M | 11.79M | 9.54M | 8.88M | 8.09M |
| Total Debt | 5.88M | 5.88M | 5.86M | 5.18M | 5.81M | 5.91M |
| Total Liabilities | 12.34M | 12.34M | 11.70M | 10.68M | 9.75M | 9.85M |
| Stockholders Equity | 32.99M | 32.99M | 32.41M | 30.68M | 28.98M | 30.08M |
Cash Flow | ||||||
| Free Cash Flow | 9.58M | 9.46M | 10.06M | 6.07M | 4.35M | 4.71M |
| Operating Cash Flow | 10.44M | 10.32M | 10.89M | 8.49M | 5.55M | 6.48M |
| Investing Cash Flow | -376.00K | -254.00K | -5.08M | -4.84M | -1.20M | -1.77M |
| Financing Cash Flow | -7.30M | -7.30M | -6.57M | -5.44M | -3.62M | -2.83M |
Tristel Technical Analysis
Tristel Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | £200.62M | 30.03 | 20.31% | 3.48% | 10.80% | 1.75% | |
70 Outperform | £10.64B | 27.70 | 9.30% | 2.35% | 2.51% | 56.56% | |
69 Neutral | £476.93M | 52.24 | 3.66% | 1.25% | 68.03% | -18.27% | |
68 Neutral | £4.76B | 28.82 | 12.73% | 2.11% | 4.18% | 37.65% | |
66 Neutral | £950.03M | 49.96 | 6.75% | 0.67% | 4.00% | -6.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | £4.20M | -3.00 | -15.46% | ― | -4.98% | -114.29% |
Tristel Corporate Events
Tristel plc has issued and allotted 84,500 new ordinary shares following the exercise of employee share options, with the shares expected to be admitted to trading on AIM on 15 January 2026. Following this admission, Tristel’s total shares in issue and total voting rights will rise to 47,850,043, a new baseline figure for shareholders assessing whether they must disclose holdings or changes in their interest under UK transparency rules.
The most recent analyst rating on (GB:TSTL) stock is a Buy with a £482.00 price target. To see the full list of analyst forecasts on Tristel stock, see the GB:TSTL Stock Forecast page.
Tristel plc announced that Tom Jenkins, a Non-Executive Director, purchased 5,400 ordinary shares in the company at a price of 368 pence per share, increasing his beneficial interest to 13,400 shares, which represents 0.03% of the total issued share capital. This transaction highlights the confidence of the company’s leadership in its market position and future prospects, potentially reassuring stakeholders about the company’s stability and growth trajectory.
The most recent analyst rating on (GB:TSTL) stock is a Buy with a £420.00 price target. To see the full list of analyst forecasts on Tristel stock, see the GB:TSTL Stock Forecast page.
Tristel plc has announced the issuance of 18,500 new ordinary shares following the exercise of employee share options. These shares are set to be admitted to trading on the AIM market of the London Stock Exchange on December 18, 2025, increasing the total number of voting rights to 47,765,543. This development allows shareholders to reassess their interests in the company’s share capital under regulatory guidelines.
The most recent analyst rating on (GB:TSTL) stock is a Buy with a £420.00 price target. To see the full list of analyst forecasts on Tristel stock, see the GB:TSTL Stock Forecast page.
At Tristel plc’s recent Annual General Meeting, all resolutions were passed, including the adoption of the company’s annual accounts, despite some opposition from proxy voting advisers. The board has committed to improving transparency and aligning future practices with best governance standards. This commitment reflects Tristel’s focus on governance best practices and sustainable growth, which is crucial for maintaining shareholder confidence and industry leadership.
The most recent analyst rating on (GB:TSTL) stock is a Buy with a £420.00 price target. To see the full list of analyst forecasts on Tristel stock, see the GB:TSTL Stock Forecast page.
Tristel plc announced a strong start to the financial year with trading aligning with expectations and a projected revenue growth of at least 10% year-on-year. The company is experiencing robust demand in the UK and Europe, with significant growth in the US market, where sales have increased by 510% compared to the previous year. This growth is driven by the adoption of Tristel’s chlorine dioxide technologies and the launch of new products, positioning the company for further expansion in the healthcare market.
The most recent analyst rating on (GB:TSTL) stock is a Buy with a £420.00 price target. To see the full list of analyst forecasts on Tristel stock, see the GB:TSTL Stock Forecast page.
Tristel plc has announced the granting of 181,972 new share options to its CEO and CFO under its Long Term Incentive Plan. The performance targets for these options are based on earnings per share and total shareholder return, reflecting adjustments for tax impacts and growth investments. This move is part of Tristel’s strategy to align leadership incentives with shareholder value, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (GB:TSTL) stock is a Buy with a £420.00 price target. To see the full list of analyst forecasts on Tristel stock, see the GB:TSTL Stock Forecast page.
Tristel plc announced that the American Institute of Ultrasound in Medicine has updated its guidelines to include chlorine dioxide as an accepted option for high-level disinfection of ultrasound probes. This inclusion marks a significant milestone for Tristel’s ULT™ foam product, which is the only FDA-cleared chlorine dioxide foam disinfectant for ultrasound probes in the US market, manufactured and distributed by Parker Laboratories under an exclusive partnership. The update, alongside the national standard recognition, is expected to accelerate the adoption of Tristel ULT™ in the US, benefiting clinicians, infection-prevention teams, and hospital administrators.
The most recent analyst rating on (GB:TSTL) stock is a Buy with a £420.00 price target. To see the full list of analyst forecasts on Tristel stock, see the GB:TSTL Stock Forecast page.
Tristel plc has announced the posting of its 2025 Annual Report and Accounts, along with the Notice of its Annual General Meeting scheduled for December 11, 2025. The company continues to focus on its growth strategy, maintaining profitability and a progressive dividend policy, which reinforces its strong market position in the infection prevention industry.
The most recent analyst rating on (GB:TSTL) stock is a Buy with a £420.00 price target. To see the full list of analyst forecasts on Tristel stock, see the GB:TSTL Stock Forecast page.
Tristel plc announced the issuance and allotment of 2,000 new ordinary shares following the exercise of employee share options. These shares are set to be admitted to trading on AIM, increasing the total number of ordinary shares and voting rights to 47,747,043. This development allows shareholders to calculate their interests in the company’s share capital under the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:TSTL) stock is a Buy with a £420.00 price target. To see the full list of analyst forecasts on Tristel stock, see the GB:TSTL Stock Forecast page.
Tristel plc has announced the issuance and allotment of 5,000 new ordinary shares following the exercise of share options by its employees. This move will increase the total number of ordinary shares and voting rights to 47,745,043, which may affect shareholders’ interests under the FCA’s Disclosure Guidance and Transparency Rules. The new shares are expected to commence trading on AIM on 16 October 2025, alongside previously announced shares, potentially impacting the company’s market positioning and shareholder calculations.
The most recent analyst rating on (GB:TSTL) stock is a Buy with a £420.00 price target. To see the full list of analyst forecasts on Tristel stock, see the GB:TSTL Stock Forecast page.
Tristel plc reported strong financial results for the year ending June 2025, with an 11% increase in turnover to £46.5m and a 23% rise in adjusted pre-tax profit to £10.1m. The company achieved significant operational milestones, including FDA clearance for a new disinfectant foam and successful insourcing of manufacturing operations. With a solid cash position and new product launches, Tristel is poised for sustained revenue growth and enhanced market positioning, particularly in the US, where demand remains high.
The most recent analyst rating on (GB:TSTL) stock is a Buy with a £420.00 price target. To see the full list of analyst forecasts on Tristel stock, see the GB:TSTL Stock Forecast page.